MA51081A - Composés modulateurs de récepteurs de type toll - Google Patents

Composés modulateurs de récepteurs de type toll

Info

Publication number
MA51081A
MA51081A MA051081A MA51081A MA51081A MA 51081 A MA51081 A MA 51081A MA 051081 A MA051081 A MA 051081A MA 51081 A MA51081 A MA 51081A MA 51081 A MA51081 A MA 51081A
Authority
MA
Morocco
Prior art keywords
toll
type receiver
receiver modulators
modulators
type
Prior art date
Application number
MA051081A
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Gregory Chin
Richard L Mackman
Samuel E Metobo
Michael R Mish
Hyung-Jung Pyun
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA51081A publication Critical patent/MA51081A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051081A 2015-03-04 2016-03-02 Composés modulateurs de récepteurs de type toll MA51081A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562128397P 2015-03-04 2015-03-04
US201562250403P 2015-11-03 2015-11-03

Publications (1)

Publication Number Publication Date
MA51081A true MA51081A (fr) 2020-10-14

Family

ID=55590135

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051081A MA51081A (fr) 2015-03-04 2016-03-02 Composés modulateurs de récepteurs de type toll
MA039601A MA39601A (fr) 2015-03-04 2016-03-02 Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA039601A MA39601A (fr) 2015-03-04 2016-03-02 Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll

Country Status (42)

Country Link
US (4) US9670205B2 (fr)
EP (3) EP3722297A1 (fr)
JP (4) JP6182278B2 (fr)
KR (3) KR102394917B1 (fr)
CN (2) CN107108615B (fr)
AU (4) AU2016216673B2 (fr)
BR (1) BR102016004764B1 (fr)
CA (1) CA2978188C (fr)
CL (1) CL2017002225A1 (fr)
CO (1) CO2017009032A2 (fr)
CR (1) CR20170395A (fr)
CU (2) CU20170115A7 (fr)
CY (2) CY1120143T1 (fr)
DK (2) DK3097102T3 (fr)
DO (1) DOP2017000203A (fr)
EA (1) EA035093B1 (fr)
EC (1) ECSP17058129A (fr)
ES (2) ES2801380T3 (fr)
HK (2) HK1226062B (fr)
HR (2) HRP20172003T1 (fr)
HU (2) HUE050029T2 (fr)
IL (1) IL254164B (fr)
LT (2) LT3321265T (fr)
MA (2) MA51081A (fr)
MD (2) MD3097102T2 (fr)
ME (1) ME02893B (fr)
MX (2) MX2020012049A (fr)
NZ (1) NZ735176A (fr)
PE (1) PE20180031A1 (fr)
PH (1) PH12017501590A1 (fr)
PL (2) PL3321265T3 (fr)
PT (2) PT3321265T (fr)
RS (1) RS56787B1 (fr)
SA (1) SA517382248B1 (fr)
SG (1) SG11201606876RA (fr)
SI (2) SI3097102T1 (fr)
SV (1) SV2017005528A (fr)
TW (1) TWI705964B (fr)
UA (1) UA123090C2 (fr)
UY (1) UY36577A (fr)
WO (1) WO2016141092A1 (fr)
ZA (2) ZA201705958B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009078A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
CA3113343A1 (fr) 2010-06-03 2011-12-08 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
EP3550031A1 (fr) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associées à la résistance aux inhibiteurs de la tyrosine kinase de bruton (btk)
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
CA2978188C (fr) 2015-03-04 2020-05-12 Gilead Sciences, Inc. Composes 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du recepteur de type toll
EP3349757A1 (fr) * 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
UA125819C2 (uk) 2015-12-15 2022-06-15 Гіліад Сайєнсіз, Інк. ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045144A1 (fr) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Composés modulateurs du recepteur de type toll
JP2019532922A (ja) * 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Pi3k−阻害剤の組み合わせ
CA3037719A1 (fr) * 2016-09-23 2018-03-29 Abbvie Inc. Reglage de dose
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
JOP20180040A1 (ar) * 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2018233648A1 (fr) * 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 Dérivé d'isothiazolo[4,3-d]pyrimidine-5,7-diamine utilisé en tant qu'agoniste de tlr8
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
US11229638B2 (en) 2017-08-22 2022-01-25 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
TW201915000A (zh) * 2017-09-22 2019-04-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
CN108069963B (zh) * 2017-11-17 2020-01-14 清华大学 吡啶并嘧啶衍生物或其盐及其制法、药物组合物和用途
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
CA3084667A1 (fr) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Conjugue de construction d'anticorps-medicament pour le traitement de l'hepatite
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
TW201945003A (zh) * 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
EP3774883A1 (fr) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (fr) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
EP3822271A4 (fr) * 2018-07-03 2022-04-13 Jiangsu Hengrui Medicine Co., Ltd. Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation médicale
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
WO2020010200A1 (fr) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Composés hétérocycliques thérapeutiques
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2020028097A1 (fr) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique
US20220111040A1 (en) * 2018-08-07 2022-04-14 Institute Of Biophyscis, Chinese Academy Of Sciences Method for activating cd4+t cell
US20210323977A1 (en) * 2018-08-28 2021-10-21 Hoffmann-La Roche Inc. Pyrrolidinyl amide compounds for the treatment of autoimmune disease
AU2019344868B2 (en) * 2018-09-19 2024-06-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR8 agonist
EP3860717A1 (fr) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Dérivés d'imidozopyrimidine
CN112839929B (zh) * 2018-10-19 2023-07-14 正大天晴药业集团股份有限公司 Tlr8激动剂
EP3873903B1 (fr) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Composés de 6-azabenzimidazole substitués en tant qu'inhibiteurs de hpk1
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN109336740B (zh) * 2018-11-27 2021-08-17 湖南有色郴州氟化学有限公司 一种4,4,4-三氟-1-丁醇的制备方法
WO2020162705A1 (fr) 2019-02-08 2020-08-13 성균관대학교산학협력단 Complexe agoniste du récepteur de type toll 7 ou 8-cholestérol, et son utilisation
WO2020176505A1 (fr) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Agonistes de protéine kinase c
WO2020176510A1 (fr) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Agonistes de protéine kinase c
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202212339A (zh) * 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) * 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (fr) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
BR112021023843A2 (pt) 2019-05-29 2022-01-04 Syngenta Crop Protection Ag Derivados microbiocidas
ES2951169T3 (es) * 2019-06-18 2023-10-18 Janssen Sciences Ireland Unlimited Co Profármacos de quinazolina para el tratamiento de infecciones virales y otras enfermedades
WO2020255038A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyridopyrimidine
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020257407A1 (fr) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anticorps anti-mésothéline et immunoconjugués de ceux-ci
TW202115056A (zh) * 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112174903B (zh) 2019-07-01 2022-07-12 清华大学 Tlr8的小分子调节剂
WO2021034804A1 (fr) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Formulations pharmaceutiques de ténofovir alafénamide
CN112390795A (zh) * 2019-08-19 2021-02-23 上海挚盟医药科技有限公司 一类2-氨基嘧啶类化合物及其药物组合物和用途
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
WO2021113765A1 (fr) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Méganucléases modifiées optimisées ayant une spécificité pour une séquence de reconnaissance dans un génome du virus de l'hépatite b
AU2020415322A1 (en) 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
US20230058425A1 (en) * 2020-01-02 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of pyridopyrimidine derivative and preparation method thereof
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021185312A1 (fr) * 2020-03-18 2021-09-23 正大天晴药业集团股份有限公司 Forme cristalline d'un agoniste de tlr8
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CN115996925A (zh) 2020-06-25 2023-04-21 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CN115362155B (zh) * 2020-07-22 2024-06-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
JP2023536945A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
WO2022031021A1 (fr) 2020-08-04 2022-02-10 성균관대학교산학협력단 Vaccin à arnm comprenant un adjuvant permettant un contrôle cinétique
JP2023548310A (ja) 2020-10-30 2023-11-16 アバクタ・ライフ・サイエンシーズ・リミテッド Fap活性化血清半減期延長型治療用コンジュゲート
WO2022140326A1 (fr) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Composés d'indole substitués
CN112763609B (zh) * 2020-12-25 2022-08-26 新疆医科大学第四附属医院 一种针对洋甘菊抗哮喘活性成分筛选提取工艺的研究方法
CN114907337B (zh) * 2021-02-08 2023-06-02 四川大学 靶向cdk4或cdk6的共价抑制剂及其应用
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
CN113125602A (zh) * 2021-04-16 2021-07-16 山东铂源药业有限公司 一种哌柏西利中残留溶剂的检测方法
CA3216459A1 (fr) 2021-04-23 2022-10-27 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugues et leurs procedes d'utilisation
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
EP4359415A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359411A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023078241A1 (fr) * 2021-11-05 2023-05-11 中国医药研究开发中心有限公司 Dérivés d'amines aromatiques et leur procédé de préparation et leur utilisation médicale
EP4440702A1 (fr) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Composés thérapeutiques contre l'infection par le virus du vih
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2024199000A1 (fr) * 2023-03-27 2024-10-03 西安新通药物研究股份有限公司 Dérivé de pyrido[3,2-d]pyrimidine substitué par alcynyle et son utilisation en tant qu'agoniste de tlr8

Family Cites Families (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
DE267495C (de) 1913-09-07 1913-11-20 Max Schreiber Sicherheitsschloss für schmucksachen
CH231852A (de) 1940-08-09 1944-04-15 Ig Farbenindustrie Ag Verfahren zur Herstellung eines Kondensationsproduktes.
US2581889A (en) 1948-07-07 1952-01-08 Burroughs Wellcome Co Method of preparing pyrimidopyrazines
US2665275A (en) 1948-12-22 1954-01-05 Allen & Hanburys Ltd 2, 4-diamino-7, 8-disubstituted pteridines
GB677342A (en) 1949-08-19 1952-08-13 Ici Ltd New pyrimidine derivatives and their use in the manufacture of pteridin derivatives
US2667486A (en) 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
GB763044A (en) 1952-04-18 1956-12-05 Ici Ltd Pteridin derivatives
GB785353A (en) 1953-01-30 1957-10-30 Merck & Co Inc Substituted pteridine derivatives
US2740784A (en) 1954-05-03 1956-04-03 Merck & Co Inc Process for preparing pteridines
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2939882A (en) 1958-07-21 1960-06-07 Shell Oil Co Stabilized alpha, beta-unsaturated aldehydes
US3081230A (en) 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
US3071587A (en) 1961-07-25 1963-01-01 American Cyanamid Co Cyanoethyl-pteridines
US3159628A (en) 1962-05-28 1964-12-01 Smith Kline French Lab Pteridine-5-oxide derivatives
US3122546A (en) 1962-12-03 1964-02-25 American Home Prod 4, 7-diamino-2-(substituted)-n-substituted-6-pteridinecarboxamides
US3162635A (en) 1962-08-06 1964-12-22 Searle & Co 1, 2, 3, 4-tetrahydro-2, 4-pteridinediones and intermediates
NL131481C (fr) 1965-04-15
DE1921308A1 (de) 1969-04-25 1971-01-07 Boehringer Sohn Ingelheim Herzwirksame Zubereitungen
GB1301319A (fr) 1970-07-13 1972-12-29
US3859287A (en) 1971-05-05 1975-01-07 Walter Wesley Parish Thiopteridines and process for producing same
US3843791A (en) 1973-01-11 1974-10-22 Pfizer Method of killing insects with quinazolinones and quinazoline-thiones
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU572792B2 (en) 1982-09-20 1988-05-19 Wellcome Foundation Limited, The 2-amino, 4-oxo-pteridine derivatives
DE3323932A1 (de) 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5149705A (en) 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
DE3833393A1 (de) 1988-10-01 1990-04-05 Thomae Gmbh Dr K Verwendung von pteridinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
CA2015981A1 (fr) * 1989-05-10 1990-11-10 Thomas H. Brown Composes
GB8910722D0 (en) 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
GB8912336D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
DE4009941A1 (de) 1990-03-28 1991-10-02 Thomae Gmbh Dr K Verwendung von pteridinen zur sensibilisierung resistenter plasmodien bei der malaria-chemotherapie und diese verbindungen enthaltende arzneimittel
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
CA2128205C (fr) 1992-01-27 2004-03-30 Hiroharu Matsuoka Derives du methotrexate
WO1993025712A1 (fr) 1992-06-15 1993-12-23 The Regents Of The University Of California Test de triage pour l'identification de medicaments immunosuppresseurs
HU214331B (hu) 1992-06-17 1998-03-02 Gyógyszerkutató Intézet Kft. Eljárás piperazin- és homopiperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0662834A4 (fr) 1992-09-22 1996-04-17 Cell Therapeutics Inc Nouveaux composes epoxy.
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
WO1994014065A1 (fr) 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Procedes d'identification et d'utilisation de composes immunodeprimants
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
US5641783A (en) 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5281603A (en) 1993-04-23 1994-01-25 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5521190A (en) 1993-05-27 1996-05-28 Fmc Corporation Insecticidal pterdines and 8-deazapteridines
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
WO1995013075A1 (fr) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
JPH07138238A (ja) 1993-11-16 1995-05-30 Kanebo Ltd 新規キナゾリン誘導体およびそれを有効成分とする抗腫瘍剤
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
DE4418096A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418097A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5607936A (en) 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
DE69534438T2 (de) 1994-12-29 2006-06-29 The Regents Of The University Of California, Oakland Verbindungen für Ceramid-vermittelter Signalübertragung
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6207144B1 (en) 1995-12-22 2001-03-27 Roche Diagnostics, Gmbh Polypeptides with interleukin-16 activity, process for the preparation and use thereof
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
AU2666997A (en) 1996-04-15 1997-11-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The In vitro prognostic test for progressors and non-progressors after hiv infection
ATE295847T1 (de) 1996-07-31 2005-06-15 Cmic Co Ltd Aktivsauerstoffaufnehmer enthaltende pterinderivate
KR20060094988A (ko) 1996-08-30 2006-08-30 다이이치 아스비오파마 가부시키가이샤 질소 산화물 합성효소 (nos)의 기능 저하에 의해유발되는 질환의 예방 또는 치료제
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
ES2189079T3 (es) 1998-04-24 2003-07-01 Leuven K U Res & Dev Efectos inmunosupresores de derivados de xantina 8-sustituidos.
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
JP4315300B2 (ja) * 1998-08-10 2009-08-19 大日本住友製薬株式会社 新規なキナゾリン誘導体
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
US5992713A (en) 1998-10-23 1999-11-30 Manabat; Gregorio S. Clothes hanger with slidable side attachments
AU770551B2 (en) 1998-12-28 2004-02-26 4-Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
EP1187615A2 (fr) 1999-02-02 2002-03-20 K.U. Leuven Research & Development Effets immunosuppresseurs des derives de pteridine
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
MXPA02001108A (es) 1999-09-15 2002-08-20 Warner Lambert Co Pieridinonas como inhibidores de la cinasa.
DE19944767A1 (de) 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
DE10059864A1 (de) 2000-11-30 2002-06-13 Gruenenthal Gmbh Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate
EP1382603B1 (fr) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
WO2003001887A2 (fr) 2001-06-28 2003-01-09 Essential Therapeutics, Inc. Composes heterocycliques en 8/17 et leurs utilisations comme inhibiteurs de la ligase de la d-alanyle-d-alanine
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
JP2005512972A (ja) 2001-10-12 2005-05-12 アイアールエム エルエルシー キナーゼ阻害剤足場およびそれらの調製方法
DE10202468A1 (de) 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20110050745A (ko) 2002-10-03 2011-05-16 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
WO2004037814A1 (fr) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Compositions indazolinones utiles en tant qu'inhibiteurs des kinases
WO2004065392A1 (fr) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Pyridines et pyrimidines condensees et leur utilisation en tant que ligands du recepteur alk-5
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
DE602004009696T2 (de) 2003-08-29 2008-08-28 4 Aza Ip Nv Immunosuppressive wirkungen von pteridinderivativen
CA2534549A1 (fr) 2003-09-12 2005-03-24 4 Aza Bioscience Nv Derives de pteridine pour le traitement du choc septique et de maladies liees au tnf-.alpha.
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
DE602004008312T2 (de) 2003-10-17 2008-04-17 4 Aza Ip Nv Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
EP1687002A4 (fr) 2003-11-10 2008-07-23 Synta Pharmaceuticals Corp Composes heterocycliques fusionnes
EP1699793A1 (fr) 2003-12-30 2006-09-13 Vasopharm Biotech GmbH 4-amino-7,8-dihydropteridines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter des maladies causees par une augmentation du niveau d'oxyde nitrique
US20090023917A1 (en) 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
WO2005080377A1 (fr) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha Composé ayant une activité d'inhibition du tgf-∃ et composition pharmaceutique contenant celui-ci
JP2007534735A (ja) 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CN1583747A (zh) 2004-05-26 2005-02-23 中国药科大学 蝶呤类一氧化氮合酶抑制剂
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
GB0417905D0 (en) 2004-08-11 2004-09-15 Novartis Ag Organic compounds
US7730363B2 (en) 2004-09-30 2010-06-01 Toshiba Solutions Corporation Reliability evaluation system, reliability evaluating method, and reliability evaluation program for information system
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007005408A (es) * 2004-11-09 2007-05-16 Hoffmann La Roche Compuestos de aminoquinazolinas.
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
MX2007007901A (es) * 2004-12-30 2007-11-07 4 Aza Ip Nv Pirido-(3,2-d)pirimidinas y composiciones farmaceuticas utiles para tratamiento medico.
US20090264415A2 (en) 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7418747B1 (en) 2005-06-13 2008-09-02 Myers Jason D Furniture
WO2006135993A1 (fr) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines et compositions pharmaceutiques destinees au traitement de l'hepatite c
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
MX2008010611A (es) 2006-02-17 2008-11-12 Pfizer Ltd Derivados de 3-desazapurina como moduladores de receptores similares a toll.
JP5440934B2 (ja) 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン
ATE549338T1 (de) 2006-05-24 2012-03-15 Boehringer Ingelheim Int Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009077A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés quinazoline 4,6-disubstitués et 2,4,6-trisubstitués et compositions pharmaceutiques utiles pour traiter des infections virales
DE102006033718B4 (de) 2006-07-20 2017-10-19 Siemens Aktiengesellschaft Elektrische Maschine mit schräg verlaufenden Magnetpolgrenzen
WO2008009078A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008077650A1 (fr) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines utiles pour le traitement d'infections virales
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
TWI434849B (zh) 2007-06-29 2014-04-21 Gilead Sciences Inc 類鐸(Toll-like)受體7之調節劑
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
EP2220046B1 (fr) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2010002998A1 (fr) 2008-07-03 2010-01-07 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines trisubstituées en position 2,4,6 utiles pour traiter des infections virales
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP2313111B1 (fr) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Formulations d'agoniste des récepteurs de type toll et leur utilisation
WO2010019702A2 (fr) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Agents de liaison à ddr1 et leurs méthodes d'utilisation
WO2010042489A2 (fr) 2008-10-06 2010-04-15 Emory University Inhibiteurs de la protéine de choc thermique 90 dérivés d'aminoquinoline, leurs procédés de préparation et leurs procédés d'utilisation
GB0819593D0 (en) 2008-10-24 2008-12-03 Ucb Pharma Sa Therapeutic agents
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
WO2010092340A1 (fr) 2009-02-13 2010-08-19 Ucb Pharma S.A. Dérivés condensés de pyridine et de pyrazine en tant qu'inhibiteurs de kinases
NZ706236A (en) 2009-05-13 2016-07-29 Gilead Pharmasset Llc Antiviral compounds
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011022508A2 (fr) 2009-08-18 2011-02-24 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées comme modulateurs des récepteurs de type toll
PL2467380T3 (pl) 2009-08-18 2017-09-29 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora typu Toll
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
CA2789022A1 (fr) 2010-02-04 2011-08-11 Gilead Biologics, Inc. Anticorps qui se lient a loxl2 (lysyl oxydase-like 2) et procedes d'utilisation de ceux-ci
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
FR2959510B1 (fr) 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
WO2011139637A1 (fr) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Modulateurs à petite molécule de stabilité de capside de vih-1 et procédés pour ceux-ci
MY189483A (en) 2010-05-31 2022-02-16 Ono Pharmaceutical Co Purinone derivative
BR112013000043A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido naft-2-ilacético para tratar aids
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
KR101930179B1 (ko) 2010-08-27 2018-12-17 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 9에 대한 항체
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
CA2812787A1 (fr) 2010-10-01 2012-04-05 Robert Hershberg Methodes de traitement de maladies allergiques
US8940740B2 (en) 2010-10-28 2015-01-27 Southern Research Institute Small molecule inhibitors of bacterial motility and a high throughput screening assay for their identification
EP2637669A4 (fr) * 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Composés hétérocycliques et utilisations de ceux-ci
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
US8664230B2 (en) 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
RS57758B1 (sr) 2011-04-08 2018-12-31 Janssen Sciences Ireland Uc Pirimidinski derivati za tretman viralnih infekcija
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
KR102038895B1 (ko) 2011-05-18 2019-10-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 기타 질환 치료용 퀴나졸린 유도체
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2734520B1 (fr) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ddr1抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013060881A1 (fr) * 2011-10-27 2013-05-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Pyridopyrimidines et leur utilisation thérapeutique
MX353548B (es) 2011-11-29 2018-01-18 Ono Pharmaceutical Co Clorhidrato derivado de purinona.
WO2013090840A1 (fr) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Dérivés de 2-amino-pyrido[3,2-d]pyrimidine en tant qu'inhibiteurs du vhc
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
EA039373B1 (ru) 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
CA2873984A1 (fr) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibiteurs de l'activite du complexe (iii) de la chaine de transport d'electrons mitochondriale et utilisation de ceux-ci
PL2859009T3 (pl) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Makrocykliczne inhibitory wirusów flaviviridae
MX2014014766A (es) 2012-06-08 2015-05-11 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae.
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CN109232439A (zh) 2012-08-10 2019-01-18 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
PL2890683T3 (pl) 2012-08-28 2017-06-30 Janssen Sciences Ireland Uc Pochodne skondensowanego bicyklicznego sulfamylu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
MA37942B1 (fr) 2012-09-10 2020-01-31 Hoffmann La Roche Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US9663474B2 (en) * 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
CN104968200B (zh) 2013-02-01 2018-03-06 维尔斯达医疗公司 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
US9598378B2 (en) 2013-02-21 2017-03-21 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
WO2014165128A2 (fr) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Agents antiviraux contre l'hépatite b
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
NO2865735T3 (fr) 2013-07-12 2018-07-21
PT3252058T (pt) 2013-07-12 2021-03-09 Gilead Sciences Inc Compostos policíclicos-carbamoílpiridona e seu uso para o tratamento de infecções por hiv
JP6401788B2 (ja) 2013-07-30 2018-10-10 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療用チエノ[3,2−d]ピリミジン誘導体
AU2015274635B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2978188C (fr) 2015-03-04 2020-05-12 Gilead Sciences, Inc. Composes 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du recepteur de type toll
EP3349757A1 (fr) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
CA3027471A1 (fr) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines pour le traitement d'infections virales

Also Published As

Publication number Publication date
EP3097102B1 (fr) 2017-10-18
ZA201806702B (en) 2022-10-26
EP3722297A1 (fr) 2020-10-14
ZA201705958B (en) 2022-10-26
HUE038059T2 (hu) 2018-10-29
KR20170114273A (ko) 2017-10-13
EA035093B1 (ru) 2020-04-27
JP2021046456A (ja) 2021-03-25
AU2020286178A1 (en) 2021-01-07
PT3097102T (pt) 2018-01-22
LT3321265T (lt) 2020-07-27
HK1226062B (zh) 2017-09-22
MA39601A (fr) 2016-11-30
CU20180011A7 (es) 2018-06-05
CA2978188C (fr) 2020-05-12
CO2017009032A2 (es) 2017-11-10
HRP20201075T1 (hr) 2020-10-30
CA2978188A1 (fr) 2016-09-09
UY36577A (es) 2016-09-30
KR20160113243A (ko) 2016-09-28
EP3321265B1 (fr) 2020-05-06
IL254164B (en) 2021-05-31
JP6182278B2 (ja) 2017-08-16
HRP20172003T1 (hr) 2018-02-23
LT3097102T (lt) 2018-01-25
PL3321265T3 (pl) 2020-11-16
ES2656225T3 (es) 2018-02-26
JP2017509667A (ja) 2017-04-06
IL254164A0 (en) 2017-10-31
SV2017005528A (es) 2018-11-29
AU2018282291B2 (en) 2020-09-10
HUE050029T2 (hu) 2020-11-30
AU2017202755B2 (en) 2018-09-20
KR101756050B1 (ko) 2017-07-07
WO2016141092A1 (fr) 2016-09-09
SI3097102T1 (en) 2018-02-28
BR102016004764B1 (pt) 2020-07-14
DK3097102T3 (en) 2018-01-22
EP3097102A1 (fr) 2016-11-30
TWI705964B (zh) 2020-10-01
AU2020286178B2 (en) 2022-11-17
AU2016216673B2 (en) 2017-02-02
RS56787B1 (sr) 2018-04-30
US20170281627A1 (en) 2017-10-05
CY1123226T1 (el) 2021-10-29
TW201639841A (zh) 2016-11-16
AU2018282291A1 (en) 2019-01-17
US20220218709A1 (en) 2022-07-14
CN107108615A (zh) 2017-08-29
AU2016216673A1 (en) 2016-09-22
NZ735176A (en) 2022-04-29
US20190282576A1 (en) 2019-09-19
UA123090C2 (uk) 2021-02-17
SG11201606876RA (en) 2016-10-28
KR102394917B1 (ko) 2022-05-09
US10285990B2 (en) 2019-05-14
CY1120143T1 (el) 2018-12-12
HK1254205A1 (zh) 2019-07-12
JP6820241B2 (ja) 2021-01-27
PH12017501590A1 (en) 2018-02-05
EA201791782A1 (ru) 2018-05-31
CU20170115A7 (es) 2018-03-13
JP2017203033A (ja) 2017-11-16
MX2017011307A (es) 2017-10-20
CN112174960A (zh) 2021-01-05
MD20170081A2 (ro) 2018-03-31
CN112174960B (zh) 2023-10-10
PT3321265T (pt) 2020-07-07
US20160289229A1 (en) 2016-10-06
AU2017202755C1 (en) 2019-01-17
EP3321265A1 (fr) 2018-05-16
MD3097102T2 (ro) 2018-02-28
ECSP17058129A (es) 2017-10-31
JP2023083474A (ja) 2023-06-15
MX2020012049A (es) 2022-10-03
DOP2017000203A (es) 2017-10-15
CL2017002225A1 (es) 2018-04-13
ES2801380T3 (es) 2021-01-11
PE20180031A1 (es) 2018-01-09
SI3321265T1 (sl) 2020-07-31
CR20170395A (es) 2017-11-07
BR102016004764A2 (pt) 2016-09-06
KR20210151993A (ko) 2021-12-14
PL3097102T3 (pl) 2018-04-30
JP7268064B2 (ja) 2023-05-02
US9670205B2 (en) 2017-06-06
ME02893B (fr) 2018-04-20
CN107108615B (zh) 2020-11-20
DK3321265T3 (da) 2020-06-08
SA517382248B1 (ar) 2022-10-30
AU2017202755A1 (en) 2017-05-18
KR102335970B1 (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
MA51081A (fr) Composés modulateurs de récepteurs de type toll
MA46093A (fr) Composés modulateurs du recepteur de type toll
MA50014A (fr) Modulateurs de k-ras
MA53943A (fr) Modulateurs de ror-gamma
MA43382A (fr) Modulateurs des récepteurs des chimiokines
MA55328A (fr) Modulateurs de ror-gamma
MA42061A (fr) Modulateurs de k-ras
DK3297438T3 (da) Ccr2-modulatorer
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3163339T3 (da) Polariseringsbevarende multikernefiber
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
MA42684A (fr) Modulateurs deutérés du récepteur toll
DK3272129T3 (da) Kommunikationssystem
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
DK3158847T3 (da) Bæreanordning
DK3179695T3 (da) Netværksautentifikation
MA43397A (fr) Pyroglutamate de vortioxetine
DK3247880T3 (da) Sammensat slickline-kommunikation
GB201505983D0 (en) Routing communiations traffic
MA51221A (fr) Composés de pyrazolopyridinone
DK3571193T3 (da) Potassium Channel Modulators
MA43791A (fr) Composés de carbapénème
FR3042089B1 (fr) Dispositif de communication ameliore